The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients

摘要: There are many active drugs to treat metastatic renal cell carcinoma (mRCC) patients who progress through their first-line vascular endothelial growth factor (VEGF) inhibitor. Many clinicians choose a second-line VEGF inhibitor based on the type of response inhibitor, without data supporting this practice. This study was conducted determine association with All mRCC in participating centers International Database Consortium were treated from January 2004 June 2011 after failure different retrospectively identified. The primary outcome is objective rate (ORR) and secondary progression-free survival (PFS) each line therapy. Of 1,602 total database patients, 464 received first- ORR therapy 22 %, 11 %. not among achieving partial versus stable disease progressive (14 % vs. 10 respectively; chi-squared trend test p = 0.17). median PFS VEGF-targeted 7.5 months (95 CI, 6.6–8.1), 3.9 3.6–4.5). no correlation between (Pearson coefficient 0.025; 0.59). clinical dependent VEGF-inhibitor. Further studies needed define parameters that predict optimize sequence RCC patients.